BC Extra | Jul 23, 2019
Company News

Biogen prioritizing new areas as it awaits SMA landscape changes

Biogen will increasingly prioritize immunology and ophthalmology to better balance risk and reward within its pipeline, executives said during the company's quarterly call Tuesday. As the biotech reported earnings that generally beat expectations, management played...
BioCentury | Apr 15, 2017
Finance

Formation focus

SV has tweaked the strategy for its sixth fund, focusing more of its biotech investment where it has made the best returns: in seed and series A investments. The firm also has diversified its LP...
BioCentury | May 16, 2016
Finance

Naurex's New Leaf

With a clinically validated MOA and a broadly applicable discovery platform, the former Naurex Inc. team convinced new investor New Leaf Venture Partners to lead a tranched $65 million series A round last week for...
BC Extra | May 10, 2016
Company News

Management tracks

Metabolic company Arena Pharmaceuticals Inc. (NASDQ:ARNA) named Amit Munshi CEO and interim principal financial officer. He was president and CEO at Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS). Epirus named Scott Rocklage, a director, CEO and promoted Chief...
BioCentury | Oct 26, 2015
Strategy

Against the wind

An unexpected slowing of Biogen Inc .'s key growth engine and two clinical setbacks in multiple sclerosis have led management to reallocate resources toward marketing support for Tecfidera dimethyl fumarate and simultaneous development of multiple...
BC Extra | May 30, 2015
Financial News

SV Life Sciences seeking $400M for sixth fund

SV Life Sciences has set a goal of $400 million for SV Life Sciences Fund VI, according to an SEC filing. The firm, which did not respond to inquiries, closed its $523 million Fund V...
BioCentury | May 25, 2015
Finance

Innovation underfed

Stephen Hansen, Associate Editor   Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone...
BC Week In Review | May 18, 2015
Company News

Calchan neurology news

Calchan transitioned from a virtual company and added Brenda Reynolds as CEO, Manjit Rahelu as COO and Zahid Ali as CSO. Reynolds and Rahelu had been with Convergence Pharmaceuticals Ltd. , which Biogen Inc. (NASDAQ:BIIB, Cambridge,...
BC Week In Review | Jan 19, 2015
Company News

Convergence Pharmaceuticals, Biogen Idec deal

Biogen is acquiring Convergence for $200 million up front and up to $475 million in milestone payments. Convergence’s CNV1014802 , a state-dependent inhibitor of sodium channel subunit Nav1.7 (SCN9A) , has completed a Phase IIa trial to...
BC Extra | Jan 13, 2015
Company News

Biogen converges on Convergence

Biogen Idec Inc. (NASDAQ:BIIB) will acquire neuropathic pain play Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) for $200 million up front. Convergence shareholders are eligible for up to $475 million in undisclosed milestones. Convergence's lead compound CNV1014802...
Items per page:
1 - 10 of 39
BC Extra | Jul 23, 2019
Company News

Biogen prioritizing new areas as it awaits SMA landscape changes

Biogen will increasingly prioritize immunology and ophthalmology to better balance risk and reward within its pipeline, executives said during the company's quarterly call Tuesday. As the biotech reported earnings that generally beat expectations, management played...
BioCentury | Apr 15, 2017
Finance

Formation focus

SV has tweaked the strategy for its sixth fund, focusing more of its biotech investment where it has made the best returns: in seed and series A investments. The firm also has diversified its LP...
BioCentury | May 16, 2016
Finance

Naurex's New Leaf

With a clinically validated MOA and a broadly applicable discovery platform, the former Naurex Inc. team convinced new investor New Leaf Venture Partners to lead a tranched $65 million series A round last week for...
BC Extra | May 10, 2016
Company News

Management tracks

Metabolic company Arena Pharmaceuticals Inc. (NASDQ:ARNA) named Amit Munshi CEO and interim principal financial officer. He was president and CEO at Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS). Epirus named Scott Rocklage, a director, CEO and promoted Chief...
BioCentury | Oct 26, 2015
Strategy

Against the wind

An unexpected slowing of Biogen Inc .'s key growth engine and two clinical setbacks in multiple sclerosis have led management to reallocate resources toward marketing support for Tecfidera dimethyl fumarate and simultaneous development of multiple...
BC Extra | May 30, 2015
Financial News

SV Life Sciences seeking $400M for sixth fund

SV Life Sciences has set a goal of $400 million for SV Life Sciences Fund VI, according to an SEC filing. The firm, which did not respond to inquiries, closed its $523 million Fund V...
BioCentury | May 25, 2015
Finance

Innovation underfed

Stephen Hansen, Associate Editor   Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone...
BC Week In Review | May 18, 2015
Company News

Calchan neurology news

Calchan transitioned from a virtual company and added Brenda Reynolds as CEO, Manjit Rahelu as COO and Zahid Ali as CSO. Reynolds and Rahelu had been with Convergence Pharmaceuticals Ltd. , which Biogen Inc. (NASDAQ:BIIB, Cambridge,...
BC Week In Review | Jan 19, 2015
Company News

Convergence Pharmaceuticals, Biogen Idec deal

Biogen is acquiring Convergence for $200 million up front and up to $475 million in milestone payments. Convergence’s CNV1014802 , a state-dependent inhibitor of sodium channel subunit Nav1.7 (SCN9A) , has completed a Phase IIa trial to...
BC Extra | Jan 13, 2015
Company News

Biogen converges on Convergence

Biogen Idec Inc. (NASDAQ:BIIB) will acquire neuropathic pain play Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) for $200 million up front. Convergence shareholders are eligible for up to $475 million in undisclosed milestones. Convergence's lead compound CNV1014802...
Items per page:
1 - 10 of 39